Mirum Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 3, 2026, reporting total assets of $1,026,613 thousand and a significant increase in convertible notes payable.

Key Highlights

  • Total assets of $1,026,613 thousand as of September 30, 2026, up from $842,813 thousand at December 31, 2025, according to the filing.
  • Cash and cash equivalents of $243,188 thousand as of September 30, 2026, compared to $296,683 thousand at December 31, 2025.
  • Convertible notes payable, net, noncurrent of $731,250 thousand as of September 30, 2026, up sharply from $309,797 thousand at December 31, 2025.
  • Accounts receivable of $156,348 thousand as of September 30, 2026, compared to $123,330 thousand at December 31, 2025.
  • 65,282,044 shares of common stock were outstanding as of October 30, 2026, the filing disclosed.
  • Holdback liabilities totaling $69,453 thousand appeared on the balance sheet as of September 30, 2026 ($24,800 thousand current and $44,653 thousand noncurrent), with no corresponding balance at December 31, 2025.

Mirum Pharmaceuticals Balance Sheet Changes Through September 30, 2026

According to the Form 10-Q filed with the SEC, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported total assets of $1,026,613 thousand as of September 30, 2026, an increase from $842,813 thousand at December 31, 2025. The company is classified as a large accelerated filer and is incorporated in Delaware, with principal offices in Foster City, California.

The filing shows current assets of $586,629 thousand as of September 30, 2026, compared to $549,684 thousand at year-end 2025. Short-term investments rose to $130,499 thousand from $86,644 thousand, while long-term investments increased substantially to $126,768 thousand from $8,105 thousand. Intangible assets, net, stood at $275,649 thousand, up from $260,921 thousand at December 31, 2025. Total liabilities grew to $1,080,799 thousand from $528,123 thousand, driven primarily by the increase in noncurrent convertible notes payable and the appearance of holdback liabilities on both a current and noncurrent basis.

The filing also includes an extensive risk factor section. Among the risks cited, the company disclosed dependence on third-party manufacturers including "certain sole-source suppliers and manufacturers," reliance on third-party licensed intellectual property, and the possibility that it "may need substantial additional financing to continue our commercialization efforts." The company noted it does not currently have patent protection or regulatory exclusivity for certain approved medicines. These are the company's own characterizations and are subject to its cautionary language.

What Was Disclosed

Mirum Pharmaceuticals filed a 10-Q for the quarter ended September 30, 2026, reporting a balance sheet with total assets of $1,026,613 thousand, total liabilities of $1,080,799 thousand, and 65,282,044 common shares outstanding as of October 30, 2026.